Evidence map›Paper›PMID 41364305›Full record

ArticleMolecular biomedicine2025

Clinicopathological characteristics, genetic aberrations, and optimized treatment strategies in double-hit and triple-hit lymphoma: a multi-center cohort study.

Yi-Ge Shen, Meng-Meng Ji, Qing Shi, Xiao-Lei Wei, Lei Fan, Ting-Bo Liu, Yao Liu, Li-Hua Dong, Ai-Bin Liang, Liang Huang and 20 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Yi-Ge Shen *State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, Shanghai, 200025, China.
Meng-Meng Ji *State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, Shanghai, 200025, China.
Qing Shi *State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, Shanghai, 200025, China.
Xiao-Lei Wei *Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Lei Fan *Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital With Nanjing Medical University, Jiangsu, China.
Ting-Bo LiuDepartment of Hematology, Fujian Provincial Key Laboratory On Hematology, Fujian Medical University Union Hospital, Fujian Institute of Hematology, Fuzhou, China.
Yao LiuDepartment of Hematology-Oncology, Chongqing University Cancer Hospital, Chongqing, China.
Li-Hua DongDepartment of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Provincial Institute of Hematology, Zhengzhou, China.
Ai-Bin LiangDepartment of Hematology, School of Medicine, Tongji Hospital, Tongji University, Shanghai, China.
Liang HuangDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hui ZhouDepartment of Lymphoma & Hematology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, Central South University, Changsha, China.
Hong-Hui HuangDepartment of Hematology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shen-Miao YangNational Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University Peoples Hospital, Beijing, China.
Xiao-Bo WangDepartment of Hematology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Yu-Yang TianDepartment of Hematology, Hainan Cancer Hospital, Haikou, China.
Zun-Min ZhuDepartment of Hematology, Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, China.
Ou BaiDepartment of Hematology, The First Hospital of Jilin University, Changchun, China.
Fei LiCenter of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Wen-Yu ShiDepartment of Oncology, Affiliated Hospital of Nantong University, Nantong, China.
Bin XuDepartment of Hematology, The First Affiliated Hospital of Xiamen University, Xiamen, China.
Xin WangDepartment of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China.
Ke-Qian ShiDepartment of Hematology, The First People's Hospital of Yunnan Province, Kunming, China.
Wei TangState Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, Shanghai, 200025, China.
Hong-Mei YiDepartment of Pathology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Si-Yuan ChenState Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, Shanghai, 200025, China.
Zhong ZhengState Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, Shanghai, 200025, China.
Shu ChengState Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, Shanghai, 200025, China.
Peng-Peng XuState Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, Shanghai, 200025, China.
Wei-Li ZhaoState Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, Shanghai, 200025, China. zhao.weili@yahoo.com.
Li WangState Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, Shanghai, 200025, China. dr_wangli@126.com.ORCID 0000-0003-2452-0169

Funding

Shanghai Science and Technology Commission's Explorer Program 25TS1404000the Clinical Research Plan of Shanghai Hospital Development Center SHDC2020CR1032Bthe National Key R&D Program of China 2022YFC2502600the National Key R&D Program of China 2023YFC3605704the National Natural Science Foundation of China 82130004the National Natural Science Foundation of China 82170178the National Natural Science Foundation of China 82200201the National Natural Science Foundation of China 82570246
6 · The paper itself

Abstract

High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements constitutes a distinct clinicopathological entity characterized by aggressive behavior, inherent resistance to conventional immunochemotherapy, and suboptimal clinical outcomes. Within our cohort, MYC/BCL2 rearrangements defined double-hit lymphoma (DHL), MYC/BCL6 as DHL-BCL6, and concurrent MYC/BCL2/BCL6 as triple-hit lymphoma (THL). Here, we delineated the clinical characteristics and genetic aberrations of 112 DHL/THL patients to investigate the factors influencing lymphoma relapse and optimize treatment strategies. Compared to 80 DHL-BCL6 patients, DHL/THL manifested distinct features, including an increased prevalence of the germinal center B-cell-like subtype and co-expression of MYC/BCL2, and demonstrated significant associations with abbreviated progression-free and overall survival. Univariate and multivariate analyses identified Ann Arbor stage and serum lactate dehydrogenase elevation as independent prognostic determinants. Therapeutic intensification employing R-DA-EDOCH was correlated with enhanced survival outcomes, while consolidative autologous stem cell transplantation significantly improved prognosis in patients who achieved remission after first-line immunochemotherapy. Regarding genetic aberrations, oncogenic mutations were detected in 102 evaluable patients. EZH2 mutation occurred more frequently in DHL/THL, while TNFRSF14 mutation exhibited greater prevalence in THL. The EZB genotype was predominantly observed in DHL/THL patients, and those with TP53 abnormalities exhibited a further diminished prognosis. In terms of the immune microenvironment, the depleted lymphoma microenvironment (LME-DP) subtype, characterized by diminished immune cell infiltration, demonstrated a propensity for increased frequency in DHL/THL patients. Collectively, these findings advance the comprehensive understanding of DHL/THL pathobiology, underscoring the imperative for novel targeted agents and therapeutic approaches.

Indexed as

LymphomaAdultAgedAged, 80 and overCohort StudiesFemaleGene RearrangementHumansMaleMiddle AgedPrognosisProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-bcl-6Proto-Oncogene Proteins c-mycBCL2 protein, humanBCL6 protein, humanMYC protein, humanProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-bcl-6Proto-Oncogene Proteins c-mycAggressive B-cell lymphomaAutologous hematopoietic stem cell transplantationDouble-hitGenetic characteristicsTargeted therapyTriple-hit

Identifiers

PMID41364305
PMCPMC12690028

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.